Oxurion Receives Transparency Notification from Atlas Special Opportunities II LLC

Leuven, Belgium – Oxurion NV, a biopharmaceutical company, announced that it has received a transparency notification from Atlas Special Opportunities II LLC. Dated June 23, 2025, the notification indicates that as of June 19, 2025, Atlas held 1,222,807 shares out of a total of 8,496,303 shares outstanding. This holding fell below the 15% threshold following the sale of voting shares.

The notification is made in accordance with Belgian transparency legislation, which requires the disclosure of significant share transactions. This sale of Atlas Special Opportunities shares impacts the shareholder structure of Oxurion, a company undergoing a transition focused on therapeutic innovation and clinical research technology.